吉利德科学公司研发的Livdelzi® (Seladelpar) 在针对原发性胆汁性胆管炎(PBC)的III期IDEAL临床试验中,取得了具有统计学意义的复合碱性磷酸酶(ALP)正常化结果。该积极数据标志着这款在研药物在治疗这一慢性肝病方面迈出了关键一步。
吉利德科学公司研发的Livdelzi® (Seladelpar) 在针对原发性胆汁性胆管炎(PBC)的III期IDEAL临床试验中,取得了具有统计学意义的复合碱性磷酸酶(ALP)正常化结果。该积极数据标志着这款在研药物在治疗这一慢性肝病方面迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.